Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
Dicerna to receive up to $201 million in upfront and success-based development and commercialization milestones, excluding royalties, for an undisclosed target The collaboration will inves......